Ipamorelin and CJC

Ipamorelin and CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) are two of the most commonly combined peptides in growth hormone research protocols. Each peptide stimulates GH release through a different mechanism, and when used together they produce a stronger, more sustained pulse than either one alone. This guide covers the dosing math, timing, and planning you need to run this stack correctly.

Understanding why this combination works requires knowing what each peptide does individually:

Think of it this way: ipamorelin tells the pituitary to release GH, and CJC-1295 (no DAC) turns up the volume on that signal. Used alone, each peptide produces a moderate GH pulse. Used together, the combined pulse is significantly larger — research suggests the synergistic effect can be 2-3x greater than either peptide alone.

Each peptide is dosed in micrograms (mcg) per injection. They are administered at the same time but drawn from separate vials:

The most widely used protocol is 200 mcg ipamorelin + 100 mcg CJC-1295 (no DAC) per injection. Some protocols use a 1:1 ratio at 100 mcg each, while more aggressive protocols push ipamorelin to 300 mcg. Start at the lower end and assess your response before increasing.

Both peptides are typically sold in 5mg vials and reconstituted separately. Never mix two different peptides in the same vial.

This concentration makes the most common doses land on clean syringe markings. At 200 mcg per injection, a single 5mg vial provides 25 doses.

Using the same water volume for both peptides keeps the math consistent. At 100 mcg per injection, a single 5mg vial provides 50 doses.